orphenadrine citrate - Profile

What are the generic drug sources for orphenadrine citrate and what is the scope of patent protection?

Orphenadrine citrate is the generic ingredient in two branded drugs marketed by Pai Holdings Pharm, Hikma, Rising, Sagent Pharms, Watson Labs, Bausch, Ascot, Lupin, Sandoz, Stevens J, and Unichem, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

Summary for orphenadrine citrate

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	15

US Patents and Regulatory Information for orphenadrine citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pai Holdings Pharm	NORFLEX	orphenadrine citrate	INJECTABLE;INJECTION	013055-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Hikma	ORPHENADRINE CITRATE	orphenadrine citrate	INJECTABLE;INJECTION	040463-001	Mar 4, 2003	AP	RX	No	No
Rising	ORPHENADRINE CITRATE	orphenadrine citrate	INJECTABLE;INJECTION	040484-001	May 24, 2006	AP	RX	No	Yes
Sagent Pharms	ORPHENADRINE CITRATE	orphenadrine citrate	INJECTABLE;INJECTION	090585-001	Aug 30, 2011	AP	RX	No	No

Last updated: February 10, 2026

mmary
Orphenadrine citrate is a muscle relaxant primarily used for symptomatic relief of muscle pain and spasms. Its therapeutic profile, regulatory status, and market potential impact its investment attractiveness. The drug has been available for decades, with a well-documented safety profile. Its growth prospects depend on patent status, competitive landscape, and demand in various markets.

---

What is the Regulatory Status of Orphenadrine Citrate?

Orphenadrine citrate is an approved drug with a long history, primarily in the US, EU, and emerging markets.

• United States: FDA-approved as a prescription medication under the monograph for muscle spasms.
• European Union: Marketed under national licenses; classified as a prescription drug.
• Other Markets: Sold as a pharmacist-compounded medicine or over-the-counter in some regions.

No recent FDA approvals or label expansions have been observed, indicating a relatively static regulatory environment. It is not currently classified as a controlled substance (Schedule classification varies by country).

---

What Are the Key Market Dynamics?

Market Size & Demand Drivers

• The global muscle relaxant market was valued at approximately $2.9 billion in 2022.
• Orphenadrine’s market share is limited relative to newer agents such as cyclobenzaprine or methocarbamol.
• Demand is driven by conditions like acute muscle spasms, lower back pain, and general musculoskeletal disorders.
• Use is primarily symptomatic with no disease modification, leading to steady but niche demand.

Competitive Landscape

• Major competitors include cyclobenzaprine, methocarbamol, carisoprodol, and tizanidine.
• Orphenadrine has a somewhat lower prescribing rate due to availability of newer agents with improved safety profiles.
• Generic status dominates, limiting pricing power and margins but supporting volume-based revenues in broader markets.

Patent and Exclusivity Status

• No active patents protecting orphenadrine citrate; the drug is off-patent globally.
• Proprietary formulations (extended-release or combination products) could offer some exclusivity but are niche.
• Constraints from generic competition impact revenue streams.

---

What Are the Patent and Commercial Risks?

Patent Expiry and Market Entry

• As a drug developed in the 1940s, it has been off patent for decades.
• No active patent protections limit commercialization and generic competition dominates.
• Entry of new, branded me-too products or biosimilars is unlikely to impact orphenadrine but could reshape the broader muscle relaxant market.

Regulatory Risks

• Minimal risk, given the longstanding approval status.
• Any new indications or formulations would require new clinical trials and regulatory approval, adding delay and expense if pursued.

Market Risks

• Demand may decline as physicians prefer newer agents with better safety profiles.
• Lack of patent protection constrains pricing power.
• Regional regulatory or reimbursement policy changes could impact sales.

---

What Is the Investment Fundamentals Outlook?

Aspect	Details	Implication
Market Position	Niche, with limited growth prospects and strong generic competition	Low revenue growth potential, but stable cash flow in existing markets
Patent Status	Off-patent globally	Generic competition limits margins
Regulatory Environment	Stable; no recent developments expected	Low regulatory risk
Market Demand	Supportive but stagnant	Limited upside apart from markets expansion
Pricing Power	Minimal due to generic availability	Marginal profit margins

Investment Considerations

• As a standalone asset, orphenadrine citrate presents limited growth and high competition risks.
• Potential value lies in niche markets, formulations, or regional expansion.
• Private or specialty pharmaceutical firms may consider development of new formulations or combinations to extend lifecycle.
• Established pharmaceutical companies could incorporate it into broader musculoskeletal product lines but face limited margin expansion.

---

Key Takeaways

• Orphenadrine citrate is an established muscle relaxant with a long patent expiry, leading to a mature, generic-driven market.
• Market demand remains stable but growth is limited, with competition from newer agents.
• Regulatory risks are minimal, but commercial risks from low margins and saturation are high.
• Investment prospects hinge on niche applications or formulation innovations rather than core sales volume.
• Entry into new markets or development of combination therapies could present incremental opportunities but require significant R&D.

---

FAQs

1. Can orphenadrine citrate be repositioned for new indications?
   Clinical trials would be required. Its primary use is symptomatic muscle relaxation; off-label or alternative indications are unlikely given current evidence.

2. What factors could improve its market outlook?
   Introduction of extended-release formulations, combination products, or regional market expansion could support growth.

3. How does the competitive landscape influence profitability?
   Genericization limits pricing; market share depends on prescriber preferences and regional formularies.

4. Are there regulatory barriers to new formulations?
   Standard approval procedures apply, but no significant barriers are foreseen given its long-established profile.

5. What is the outlook for biosimilars or biologics in this space?
   Not applicable; orphenadrine is a small molecule, not a biologic. Biosimilar concepts do not affect it directly.

---

References

[1] Market research reports on muscle relaxants, 2022.
[2] FDA drug approval data.
[3] European Medicines Agency (EMA) licensing.
[4] Industry analysis of generic drug markets, 2022.
[5] Patent database queries, 2023.